Elanco Animal Health Incorporated Quick Ratio (ELAN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Elanco Animal Health Incorporated  (NYSE: ELAN)

Elanco Animal Health Incorporated's Quick Ratio

ELAN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.29 below Elanco Animal Health Incorporated average.

Within Major Pharmaceutical Preparations industry 407 other companies have achieved higher Quick Ratio than Elanco Animal Health Incorporated in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 3017, from total ranking in the first quarter 2026 at 3349.

Explain Quick Ratio?
How much Cash & cash equivalents ELAN´s has?
What are ELAN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ELAN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 80.68 % 32.84 % 20.14 % 9.21 % 1.08 %
Y / Y Cash & cash equivalent Change -1.67 % -12.11 % 16.45 % 3.06 % 29.57 %
Quick Ratio MRQ 0.29 0.34 0.46 0.47 0.53
ELAN's Total Ranking # 3017 # 3349 # 3140 # 3058 # 3115
Seq. Current Liabilities Change 46.75 % 6.86 % 9.45 % 5.27 % 7.89 %
Seq. Cash & cash equivalent Change 23.83 % -21.47 % 7.92 % -6.31 % 10.68 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 408
Healthcare Sector # 789
Overall Market # 3095


Quick Ratio Statistics
High Average Low
2.34 0.57 0.25
(Mar 31 2020)   (Dec 31 2022)




Financial Statements
Elanco Animal Health Incorporated's Current Liabilities $ 1,852 Millions Visit ELAN's Balance sheet
Elanco Animal Health Incorporated's Cash & cash equivalent $ 530 Millions Visit ELAN's Balance sheet
Source of ELAN's Sales Visit ELAN's Sales by Geography


Cumulative Elanco Animal Health Incorporated's Quick Ratio

ELAN's Quick Ratio for the trailling 12 Months

ELAN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 36.19 % 15.55 % 8.62 % 6.52 % 6.33 %
Y / Y Cash & cash equivalent TTM Growth 1.21 % 8.38 % 20.77 % 24.7 % 33.87 %
Quick Ratio TTM 0.37 0.44 0.49 0.5 0.5
Total Ranking TTM # 2394 # 2682 # 2009 # 2034 # 2103
Seq. Current Liabilities TTM Growth 18.19 % 7.37 % 4.9 % 2.31 % 0.28 %
Seq. Cash & cash equivalent TTM Growth -0.45 % -2.84 % 3.85 % 0.76 % 6.61 %

Quick ratio ranking by company, industry and sector >> Back to ELAN Financial Strength Comparisons >> Go to Compare ELAN Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2026 to $1,852.00 millions, cumulative Quick Ratio decreased to 0.37 below the Elanco Animal Health Incorporated average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 441 other companies have achieved higher Quick Ratio than Elanco Animal Health Incorporated. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 4086.

Explain Quick Ratio?
How much Cash & cash equivalents ELAN´s has?
What are ELAN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 442
Healthcare Sector # 907
Within the Market # 3017


trailing twelve months Quick Ratio Statistics
High Average Low
1.04 0.39 0.24
(Jun 30 2020)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Moleculin Biotech Inc   0.78 $ 7.262  Millions$ 9.313  Millions
Seres Therapeutics Inc   0.78 $ 15.594  Millions$ 20.031  Millions
Travere Therapeutics Inc   0.77 $ 117.735  Millions$ 152.025  Millions
Arcus Biosciences Inc   0.77 $ 153.000  Millions$ 198.000  Millions
Alkermes Plc   0.77 $ 511.529  Millions$ 662.091  Millions
Integrated Biopharma Inc  0.77 $ 4.471  Millions$ 5.802  Millions
Cyclerion Therapeutics Inc   0.75 $ 1.391  Millions$ 1.843  Millions
Dar Bioscience Inc   0.75 $ 12.618  Millions$ 16.923  Millions
Heron Therapeutics Inc   0.70 $ 64.643  Millions$ 92.145  Millions
Amphastar Pharmaceuticals Inc   0.70 $ 331.903  Millions$ 476.848  Millions
Axsome Therapeutics Inc   0.69 $ 319.850  Millions$ 460.446  Millions
Zentalis Pharmaceuticals Inc   0.66 $ 24.783  Millions$ 37.709  Millions
Pfizer Inc  0.64 $ 20,881.000  Millions$ 32,646.000  Millions
Enanta Pharmaceuticals Inc  0.62 $ 33.419  Millions$ 54.166  Millions
60 Degrees Pharmaceuticals Inc   0.61 $ 1.023  Millions$ 1.685  Millions
Eton Pharmaceuticals Inc   0.59 $ 26.845  Millions$ 45.124  Millions
Kura Oncology Inc   0.59 $ 70.242  Millions$ 118.193  Millions
Allarity Therapeutics Inc   0.59 $ 16.982  Millions$ 28.579  Millions
Bristol myers Squibb Company  0.59 $ 11,067.000  Millions$ 18,659.000  Millions
Prestige Consumer Healthcare Inc   0.58 $ 89.127  Millions$ 153.806  Millions
Biora Therapeutics Inc   0.57 $ 21.906  Millions$ 38.687  Millions
Matinas Biopharma Holdings Inc   0.56 $ 0.761  Millions$ 1.350  Millions
Karyopharm Therapeutics Inc   0.56 $ 75.225  Millions$ 134.233  Millions
Journey Medical Corp  0.56 $ 25.643  Millions$ 45.770  Millions
Nektar Therapeutics  0.55 $ 39.267  Millions$ 70.985  Millions
Supernus Pharmaceuticals inc   0.52 $ 180.145  Millions$ 347.378  Millions
Citius Oncology Inc  0.50 $ 16.564  Millions$ 33.152  Millions
Verrica Pharmaceuticals Inc   0.50 $ 11.198  Millions$ 22.442  Millions
Aytu Biopharma Inc  0.48 $ 26.308  Millions$ 54.659  Millions
Jupiter Neurosciences Inc   0.47 $ 1.522  Millions$ 3.251  Millions

Date modified: 2026-09-08T13:46:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.